Literature DB >> 27519491

Efficacy and Tolerability of Fosinopril 10mg and Hydrochlorothiazide 12.5mg Combination in Elderly Patients with Mild to Moderate Hypertension : A French Multicentre Study.

J P Fillastre1, S Hermant2, P Huynen2, R Saini3.   

Abstract

The objective of the study was to evaluate the efficacy and tolerability of the combination of fosinopril l0mg (FOS) and hydrochlorothiazide (HCTZ) 12.5mg versus placebo in the treatment of elderly patients with mild to moderate hypertension. The study included two distinct phases: Phase I was a short-term phase consisting of a 4-week single-blind, placebo lead-in period followed by a randomised, double-blind, parallel group where patients were treated with either a combination tablet of FOS 10mg with HCTZ 12.5mg or placebo given once daily for 8 weeks. A total of 150 patients, ranging from 60 to 91 years of age, were included in this study. Phase II was a long-term extension of phase I and was a 12-month open-label follow-up in which all patients started therapy with FOS l0mg/HCTZ 12.5mg. After 4 weeks of initial therapy, escalation to FOS 20mg/HCTZ 12.5mg was allowed for seated diastolic blood pressure (SeDBP) > 90mm Hg. Clinic visits were scheduled at months 1, 3, 6, 9 and 12. Data from 118 patients were analysed. The mean SeDBP decreased from baseline more in the FOS/HCTZ group (-12.2mm Hg) than in the placebo group (-6.4mm Hg). Similar results were observed for supine diastolic and systolic blood pressure. After 8 weeks of treatment, 58.2% of patients showed normalised (≤ 90mm Hg) SeDBP with Fos/HCTZ vs 30.3% in the placebo group (p < 0.001). The mean decrease from baseline in SeDBP was -14.3mm Hg and -18.4mm Hg at 1 month and 12 months, respectively, demonstrating efficacy of the lower dose combination (10/12.5mg). The mean seated systolic blood pressure (SeSBP) also decreased from baseline and was -24.5mm Hg and -28.5mm Hg at months 1 and 12, respectively. The results for supine blood pressure corroborated the findings for seated blood pressure. Four patients died either during (2) or shortly after (2) long-term therapy, 5 patients discontinued long-term therapy because of adverse events, 14 patients experienced 16 serious adverse events. Cough was the most common adverse effect reported in 10.4% of patients. No symptomatic orthostatic hypotension was reported.Fosinopril 10 or 20mg when administered in combination with hydrochlorothiazide 12.5mg once daily for 12 months was found to be an effective antihypertensive treatment in elderly patients with mild to moderate hypertension.

Entities:  

Year:  1997        PMID: 27519491     DOI: 10.2165/00044011-199713060-00002

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  10 in total

Review 1.  Systolic hypertension in the elderly program (SHEP) and Swedish trial in old patients with hypertension (STOP). The promises and the potential problems.

Authors:  N M Kaplan
Journal:  Am J Hypertens       Date:  1992-05       Impact factor: 2.689

2.  Pharmacokinetics, safety, and pharmacologic effects of fosinopril sodium, an angiotensin-converting enzyme inhibitor in healthy subjects.

Authors:  K L Duchin; A P Waclawski; J I Tu; J Manning; M Frantz; D A Willard
Journal:  J Clin Pharmacol       Date:  1991-01       Impact factor: 3.126

3.  Disposition of fosinopril sodium in healthy subjects.

Authors:  S M Singhvi; K L Duchin; R A Morrison; D A Willard; D W Everett; M Frantz
Journal:  Br J Clin Pharmacol       Date:  1988-01       Impact factor: 4.335

Review 4.  Role of angiotensin in autoregulation of cerebral blood flow.

Authors:  O B Paulson; G Waldemar; A R Andersen; D I Barry; E V Pedersen; J F Schmidt; S Vorstrup
Journal:  Circulation       Date:  1988-06       Impact factor: 29.690

5.  Antihypertensive effect of fosinopril, a new angiotensin converting enzyme inhibitor: findings of the Fosinopril Study Group II.

Authors:  J L Pool
Journal:  Clin Ther       Date:  1990 Nov-Dec       Impact factor: 3.393

6.  Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group.

Authors: 
Journal:  JAMA       Date:  1979-12-07       Impact factor: 56.272

Review 7.  Hypertension in the elderly. Implications and generalizability of randomized trials.

Authors:  C D Mulrow; J A Cornell; C R Herrera; A Kadri; L Farnett; C Aguilar
Journal:  JAMA       Date:  1994-12-28       Impact factor: 56.272

8.  Antihypertensive efficacy and influence on physical activity of three different treatments in elderly hypertensive patients.

Authors:  G Leonetti; C Mazzola; C Pasotti; L Angioni; A Vaccarella; A Capra; G Botta; A Zanchetti
Journal:  J Hypertens Suppl       Date:  1989-12

9.  Once-daily fosinopril in the treatment of hypertension.

Authors:  R J Anderson; K L Duchin; R D Gore; T S Herman; R S Michaels; P S Nichola; T M Nolen; P Wolfson; D G Wombolt; R Zusman
Journal:  Hypertension       Date:  1991-05       Impact factor: 10.190

10.  Fosinopril, a phosphinic acid inhibitor of angiotensin I converting enzyme: in vitro and preclinical in vivo pharmacology.

Authors:  J M DeForrest; T L Waldron; C Harvey; B Scalese; B Rubin; J R Powell; E W Petrillo; D W Cushman
Journal:  J Cardiovasc Pharmacol       Date:  1989-11       Impact factor: 3.105

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.